Abstract

Knowledge of mucins and their multiple roles in various normal and pathological processes has improved greatly in the past two decades. Mucins belong to a family of glycoproteins characterised by densely O-glycosylated repetitive domains and expressed by various surface epithelial cells. Altered expression of mucins is present in various diseases, including cancer. Ovarian cancer is the sixth most common cancer worldwide and the seventh leading cause of cancer-related deaths in women. The most common ovarian cancer is epithelial ovarian carcinoma, which is characterised by few early symptoms, widespread peritoneal dissemination, and ascites at advanced stages that result in poor prognosis. After diagnosis, 5 year survival is only 35-45%. Therefore, improved strategies for early diagnosis and treatment are needed. Because of the surface epithelial origin of epithelial ovarian cancer, mucins are obvious biomolecules for investigation as markers for early diagnosis and as therapeutic targets. We discuss the potential role and clinical usefulness of mucins in early diagnosis, prognosis, and treatment of ovarian cancer.

Original languageEnglish (US)
Pages (from-to)1076-1085
Number of pages10
JournalThe Lancet Oncology
Volume9
Issue number11
DOIs
StatePublished - Nov 1 2008

Fingerprint

Mucins
Ovarian Neoplasms
Early Diagnosis
Therapeutics
Neoplasms
Pathologic Processes
Ascites
Glycoproteins
Epithelial Cells
Carcinoma
Survival
Ovarian epithelial cancer

ASJC Scopus subject areas

  • Oncology

Cite this

@article{5557825141d94d8e80730bb05ec37af9,
title = "Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer",
abstract = "Knowledge of mucins and their multiple roles in various normal and pathological processes has improved greatly in the past two decades. Mucins belong to a family of glycoproteins characterised by densely O-glycosylated repetitive domains and expressed by various surface epithelial cells. Altered expression of mucins is present in various diseases, including cancer. Ovarian cancer is the sixth most common cancer worldwide and the seventh leading cause of cancer-related deaths in women. The most common ovarian cancer is epithelial ovarian carcinoma, which is characterised by few early symptoms, widespread peritoneal dissemination, and ascites at advanced stages that result in poor prognosis. After diagnosis, 5 year survival is only 35-45{\%}. Therefore, improved strategies for early diagnosis and treatment are needed. Because of the surface epithelial origin of epithelial ovarian cancer, mucins are obvious biomolecules for investigation as markers for early diagnosis and as therapeutic targets. We discuss the potential role and clinical usefulness of mucins in early diagnosis, prognosis, and treatment of ovarian cancer.",
author = "Singh, {Ajay P.} and Shantibhusan Senapati and {Palanimuthu Ponnusamy}, Moorthy and Maneesh Jain and Lele, {Subodh M} and Davis, {John S} and Remmenga, {Steven W} and Batra, {Surinder Kumar}",
year = "2008",
month = "11",
day = "1",
doi = "10.1016/S1470-2045(08)70277-8",
language = "English (US)",
volume = "9",
pages = "1076--1085",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "11",

}

TY - JOUR

T1 - Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer

AU - Singh, Ajay P.

AU - Senapati, Shantibhusan

AU - Palanimuthu Ponnusamy, Moorthy

AU - Jain, Maneesh

AU - Lele, Subodh M

AU - Davis, John S

AU - Remmenga, Steven W

AU - Batra, Surinder Kumar

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Knowledge of mucins and their multiple roles in various normal and pathological processes has improved greatly in the past two decades. Mucins belong to a family of glycoproteins characterised by densely O-glycosylated repetitive domains and expressed by various surface epithelial cells. Altered expression of mucins is present in various diseases, including cancer. Ovarian cancer is the sixth most common cancer worldwide and the seventh leading cause of cancer-related deaths in women. The most common ovarian cancer is epithelial ovarian carcinoma, which is characterised by few early symptoms, widespread peritoneal dissemination, and ascites at advanced stages that result in poor prognosis. After diagnosis, 5 year survival is only 35-45%. Therefore, improved strategies for early diagnosis and treatment are needed. Because of the surface epithelial origin of epithelial ovarian cancer, mucins are obvious biomolecules for investigation as markers for early diagnosis and as therapeutic targets. We discuss the potential role and clinical usefulness of mucins in early diagnosis, prognosis, and treatment of ovarian cancer.

AB - Knowledge of mucins and their multiple roles in various normal and pathological processes has improved greatly in the past two decades. Mucins belong to a family of glycoproteins characterised by densely O-glycosylated repetitive domains and expressed by various surface epithelial cells. Altered expression of mucins is present in various diseases, including cancer. Ovarian cancer is the sixth most common cancer worldwide and the seventh leading cause of cancer-related deaths in women. The most common ovarian cancer is epithelial ovarian carcinoma, which is characterised by few early symptoms, widespread peritoneal dissemination, and ascites at advanced stages that result in poor prognosis. After diagnosis, 5 year survival is only 35-45%. Therefore, improved strategies for early diagnosis and treatment are needed. Because of the surface epithelial origin of epithelial ovarian cancer, mucins are obvious biomolecules for investigation as markers for early diagnosis and as therapeutic targets. We discuss the potential role and clinical usefulness of mucins in early diagnosis, prognosis, and treatment of ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=54349122044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54349122044&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(08)70277-8

DO - 10.1016/S1470-2045(08)70277-8

M3 - Review article

C2 - 19012856

AN - SCOPUS:54349122044

VL - 9

SP - 1076

EP - 1085

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 11

ER -